Revvity Valuation

Is RVTY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVTY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RVTY ($123.96) is trading below our estimate of fair value ($588.66)

Significantly Below Fair Value: RVTY is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVTY?

Other financial metrics that can be useful for relative valuation.

RVTY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.4x
Enterprise Value/EBITDA22.2x
PEG Ratio3x

Price to Earnings Ratio vs Peers

How does RVTY's PE Ratio compare to its peers?

The above table shows the PE ratio for RVTY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average71.7x
AVTR Avantor
47.8x25.5%US$17.1b
QGEN Qiagen
133.2x34.3%US$9.7b
TECH Bio-Techne
70.6x18.3%US$11.7b
WAT Waters
35.1x8.2%US$21.0b
RVTY Revvity
77.5x25.8%US$15.3b

Price-To-Earnings vs Peers: RVTY is expensive based on its Price-To-Earnings Ratio (77.5x) compared to the peer average (71.7x).


Price to Earnings Ratio vs Industry

How does RVTY's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: RVTY is expensive based on its Price-To-Earnings Ratio (77.5x) compared to the Global Life Sciences industry average (34.8x).


Price to Earnings Ratio vs Fair Ratio

What is RVTY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVTY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio77.5x
Fair PE Ratio34.3x

Price-To-Earnings vs Fair Ratio: RVTY is expensive based on its Price-To-Earnings Ratio (77.5x) compared to the estimated Fair Price-To-Earnings Ratio (34.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVTY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$123.96
US$134.48
+8.5%
7.7%US$162.00US$120.00n/a18
Sep ’25US$122.54
US$133.87
+9.2%
7.8%US$162.00US$120.00n/a18
Aug ’25US$125.03
US$134.10
+7.3%
7.9%US$162.00US$120.00n/a17
Jul ’25US$103.00
US$124.04
+20.4%
9.9%US$162.00US$105.00n/a16
Jun ’25US$109.26
US$123.67
+13.2%
10.3%US$162.00US$105.00n/a16
May ’25US$102.60
US$123.61
+20.5%
10.3%US$162.00US$105.00n/a16
Apr ’25US$103.27
US$123.11
+19.2%
10.6%US$162.00US$100.00n/a16
Mar ’25US$107.12
US$123.11
+14.9%
10.6%US$162.00US$100.00n/a16
Feb ’25US$109.26
US$117.66
+7.7%
15.1%US$162.00US$85.00n/a16
Jan ’25US$109.31
US$104.79
-4.1%
16.5%US$162.00US$85.00n/a17
Dec ’24US$91.28
US$106.71
+16.9%
17.0%US$162.00US$85.00n/a14
Nov ’24US$82.54
US$106.71
+29.3%
17.0%US$162.00US$85.00n/a14
Oct ’24US$110.70
US$143.24
+29.4%
9.9%US$170.00US$120.00US$124.4416
Sep ’24US$116.92
US$144.31
+23.4%
9.1%US$170.00US$125.00US$122.5416
Aug ’24US$122.63
US$143.74
+17.2%
9.9%US$170.00US$120.00US$125.0316
Jul ’24US$118.79
US$145.53
+22.5%
11.1%US$170.00US$120.00US$103.0015
Jun ’24US$115.67
US$147.19
+27.3%
11.4%US$170.00US$120.00US$109.2615
May ’24US$130.26
US$155.78
+19.6%
9.1%US$182.00US$134.00US$102.6014
Apr ’24US$133.26
US$158.92
+19.3%
8.0%US$182.00US$140.00US$103.2712
Mar ’24US$123.50
US$158.92
+28.7%
8.0%US$182.00US$140.00US$107.1212
Feb ’24US$139.27
US$160.00
+14.9%
8.3%US$185.00US$140.00US$109.2612
Jan ’24US$140.22
US$157.92
+12.6%
9.3%US$178.00US$127.00US$109.3112
Dec ’23US$141.75
US$156.18
+10.2%
12.0%US$192.00US$127.00US$91.2811
Nov ’23US$136.57
US$166.91
+22.2%
14.1%US$202.00US$120.00US$82.5411
Oct ’23US$120.33
US$171.27
+42.3%
9.6%US$202.00US$140.00US$110.7011

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies